Cover Image
Market Research Report

Neuropsychiatric Disorder Cluster Drug Development Pipeline Review, 2017

Published by GlobalData Product code 537172
Published Content info 254 Pages
Delivery time: 1-2 business days
Price
Back to Top
Neuropsychiatric Disorder Cluster Drug Development Pipeline Review, 2017
Published: August 1, 2017 Content info: 254 Pages
Description

Executive Summary:

Attention deficit hyperactivity disorder (ADHD) is a group of behavioral symptoms that include inattentiveness, hyperactivity and impulsiveness, withsymptoms including disorganized work habits, procrastination and inability to sustain attention on tasks or activities. There are a total of 61 products in development for this indication, by 40 companies and five academic institutions. Key companies operating in this pipeline space include NLS Pharma Group and Shire.

Depression is a mood disorder that causes a persistent feeling of sadness and loss of interest. Signs and symptoms include sleep disturbances, including insomnia or sleeping too much, changes in appetite, anxiety, agitation or restlessness and physical problems, such as back pain or headaches. There are a total of 191 products in development for this indication, by 112 companies and 20 academic institutions. Key companies operating in this pipeline space include Johnson & Johnson, Sumitomo Dainippon Pharma, Luye Pharma Group, Otsuka Holdings and Vanderbilt University.

Schizophrenia is a chronic, severe, and disabling brain disorder that generally appears in late adolescence or early adulthood. Symptoms include delusions, hallucinations, disorganized speech and disorganized behavior. There are a total of 134 products in development for this indication, by 85 companies and nine academic institutions. Key companies operating in this pipeline space include Omeros Corp, Suven Life Sciences, Heptares Therapeutics, Merck & Co, Sumitomo Dainippon Pharma and Vanderbilt University.

Finally, Tourette syndrome is a neurological disorder characterized by repetitive, stereotyped, involuntary movements and vocalizations called tics. Symptoms include eye blinking and other eye movements, facial grimacing, shoulder shrugging, and head or shoulder jerking. There are a total of 11 products in development for this indication, by nine companies and one academic institution. Key companies operating in this pipeline space include Catalyst Pharmaceuticals, who are fielding two pipeline products.

Across all four of these indications, transporters and receptors of neurotransmitters such as dopamine and serotonin are the most common targets, closely reflecting the current treatment landscape of these diseases.

The report " Neuropsychiatric Disorder Cluster Drug Development Pipeline Review, 2017", provides an overview of the pipeline landscape for neuropsychiatric disorders. The report provides comprehensive information on the therapeutics under development and key players involved in therapeutic development for Attention Deficit Hyperactivity Disorder (ADHD), Depression, Schizophrenia, and Tourette syndrome, and features dormant and discontinued projects.

Scope:

  • Which companies are the most active within the pipeline for genetic neuropsychiatric disorder therapeutics?
  • Which pharmaceutical approaches are the most prominent at each stage of the pipeline and within each indication?
  • To what extent do universities and institutions play a role within this pipeline, compared to pharmaceutical companies?
  • What are the most important R&D milestones and data publications to have happened in the field of genetic neuropsychiatric disorders?

Reasons to buy:

  • Understand the overall pipeline, with an at-a-glance overview of all products in therapeutic development for each indication
  • Assess the products in development in granular detail, with an up-to-date overview of each individual pipeline program in each indication, and a comprehensive picture of recent updates and milestones for each
  • Analyze the companies, institutions and universities currently operating in the pipeline, and the products being fielded by each of these
  • Understand the composition of the pipeline in terms of molecule type, molecular target, mechanism of action and route of administration
Table of Contents
Product Code: GBIHC017IDB

Table of Contents

  • GBI Research Report Guidance
  • Executive Summary
  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Neuropsychiatric Disorder Cluster Report Coverage
    • Attention Deficit Hyperactivity Disorder (ADHD) - Overview
    • Depression - Overview
    • Schizophrenia - Overview
    • Tourette Syndrome - Overview
  • Therapeutics Development
    • Attention Deficit Hyperactivity Disorder (ADHD)
    • Depression
    • Schizophrenia
    • Tourette Syndrome
  • Therapeutics Assessment
    • Attention Deficit Hyperactivity Disorder (ADHD)
    • Depression
    • Schizophrenia
    • Tourette Syndrome
  • Companies Involved in Therapeutics Development
    • Attention Deficit Hyperactivity Disorder (ADHD)
    • Depression
    • Schizophrenia
    • Tourette Syndrome
  • Dormant Projects
    • Attention Deficit Hyperactivity Disorder (ADHD)
    • Depression
    • Schizophrenia
    • Tourette Syndrome
  • Discontinued Products
    • Attention Deficit Hyperactivity Disorder (ADHD)
    • Depression
    • Schizophrenia
    • Tourette Syndrome
  • Product Development Milestones
    • Attention Deficit Hyperactivity Disorder (ADHD)
    • Depression
    • Schizophrenia
    • Tourette Syndrome
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Attention Deficit Hyperactivity Disorder (ADHD)
  • Number of Products under Development by Companies, Attention Deficit Hyperactivity Disorder (ADHD)
  • Number of Products under Development by Universities/Institutes, Attention Deficit Hyperactivity Disorder (ADHD)
  • Products under Development by Companies, Attention Deficit Hyperactivity Disorder (ADHD)
  • Products under Development by Universities/Institutes, Attention Deficit Hyperactivity Disorder (ADHD)
  • Number of Products under Development for Depression
  • Number of Products under Development by Companies, Depression
  • Number of Products under Development by Universities/Institutes, Depression
  • Products under Development by Companies, Depression
  • Products under Development by Universities/Institutes, Depression
  • Number of Products under Development for Schizophrenia
  • Number of Products under Development by Companies, Schizophrenia
  • Number of Products under Development by Universities/Institutes, Schizophrenia
  • Products under Development by Companies, Schizophrenia
  • Products under Development by Universities/Institutes, Schizophrenia
  • Number of Products under Development for Tourette Syndrome
  • Number of Products under Development by Companies, Tourette Syndrome
  • Number of Products under Development by Universities/Institutes, Tourette Syndrome
  • Products under Development by Companies, Tourette Syndrome
  • Products under Development by Universities/Institutes, Tourette Syndrome
  • Number of Products by Stage and Target, Attention Deficit Hyperactivity Disorder (ADHD)
  • Number of Products by Stage and Mechanism of Action, Attention Deficit Hyperactivity Disorder (ADHD)
  • Number of Products by Stage and Route of Administration, Attention Deficit Hyperactivity Disorder (ADHD)
  • Number of Products by Stage and Molecule Type, Attention Deficit Hyperactivity Disorder (ADHD)
  • Number of Products by Stage and Target, Depression
  • Number of Products by Stage and Mechanism of Action, Depression
  • Number of Products by Stage and Route of Administration, Depression
  • Number of Products by Stage and Molecule Type, Depression
  • Number of Products by Stage and Target, Schizophrenia
  • Number of Products by Stage and Mechanism of Action, Schizophrenia
  • Number of Products by Stage and Route of Administration, Schizophrenia
  • Number of Products by Stage and Molecule Type, Schizophrenia
  • Number of Products by Stage and Target, Tourette Syndrome
  • Number of Products by Stage and Mechanism of Action, Tourette Syndrome
  • Number of Products by Stage and Route of Administration, Tourette Syndrome
  • Number of Products by Stage and Molecule Type, Tourette Syndrome
  • Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Aevi Genomic Medicine Inc
  • Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Alcobra Ltd
  • Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Amarantus Bioscience Holdings Inc
  • Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by APeT Holding BV
  • Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Arbor Pharmaceuticals LLC
  • Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by BCWorld Pharm Co Ltd
  • Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by BioHealthonomics Inc
  • Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by BioLite Inc
  • Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Cingulate Therapeutics LLC
  • Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Collegium Pharmaceutical Inc
  • Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Curemark LLC
  • Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by DURECT Corp
  • Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Eli Lilly and Company
  • Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Ensysce Biosciences Inc
  • Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by H. Lundbeck A/S
  • Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Heptares Therapeutics Ltd
  • Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Highland Therapeutics Inc
  • Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Integrative Research Laboratories Sweden AB
  • Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by INVENT Pharmaceuticals Inc
  • Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by KemPharm Inc
  • Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Luc Therapeutics Inc
  • Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Merck & Co Inc
  • Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Neos Therapeutics Inc
  • Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by NeuroDerm Ltd
  • Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Neurovance Inc
  • Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by NLS Pharma Group
  • Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Noven Pharmaceuticals Inc
  • Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by P2D Bioscience
  • Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Reviva Pharmaceuticals Inc
  • Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Shire Plc
  • Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by SK Biopharmaceuticals Co Ltd
  • Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Sunovion Pharmaceuticals Inc
  • Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Supernus Pharmaceuticals Inc
  • Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Taisho Pharmaceutical Co Ltd
  • Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by TRImaran Pharma Inc
  • Depression - Pipeline by 4D Pharma PLC
  • Depression - Pipeline by AB Science SA
  • Depression - Pipeline by Acadia Pharmaceuticals Inc
  • Depression - Pipeline by Adamed Sp z oo
  • Depression - Pipeline by Addex Therapeutics Ltd
  • Depression - Pipeline by Aequus Pharmaceuticals Inc
  • Depression - Pipeline by Alkermes Plc
  • Depression - Pipeline by Allergan Plc
  • Depression - Pipeline by Alvogen Korea Co Ltd
  • Depression - Pipeline by Amorsa Therapeutics Inc
  • Depression - Pipeline by Anavex Life Sciences Corp
  • Depression - Pipeline by Angelini Group
  • Depression - Pipeline by Angita BV
  • Depression - Pipeline by Araim Pharmaceuticals Inc
  • Depression - Pipeline by AstraZeneca Plc
  • Depression - Pipeline by Avanir Pharmaceuticals Inc
  • Depression - Pipeline by Axsome Therapeutics Inc
  • Depression - Pipeline by Azevan Pharmaceuticals Inc
  • Depression - Pipeline by BioCrea GmbH
  • Depression - Pipeline by BioLite Inc
  • Depression - Pipeline by Bionomics Ltd
  • Depression - Pipeline by Boehringer Ingelheim GmbH
  • Depression - Pipeline by Bristol-Myers Squibb Company
  • Depression - Pipeline by Calico LLC
  • Depression - Pipeline by Celgene Corp
  • Depression - Pipeline by Celon Pharma SA
  • Depression - Pipeline by Cerecor Inc
  • Depression - Pipeline by Clera Inc
  • Depression - Pipeline by Delpor Inc
  • Depression - Pipeline by Domain Therapeutics SA
  • Depression - Pipeline by Eisai Co Ltd
  • Depression - Pipeline by Eli Lilly and Company
  • Depression - Pipeline by Evotec AG
  • Depression - Pipeline by F. Hoffmann-La Roche Ltd
  • Depression - Pipeline by Fabre-Kramer Pharmaceuticals Inc
  • Depression - Pipeline by FPRT Bio Inc
  • Depression - Pipeline by GlaxoSmithKline Plc
  • Depression - Pipeline by GliaCure Inc
  • Depression - Pipeline by H. Lundbeck A/S
  • Depression - Pipeline by Heptares Therapeutics Ltd
  • Depression - Pipeline by Hua Medicine (Shanghai) Ltd
  • Depression - Pipeline by Hyundai Pharmaceutical Co Ltd
  • Depression - Pipeline by Impel NeuroPharma Inc
  • Depression - Pipeline by INSYS Therapeutics Inc
  • Depression - Pipeline by Intas Pharmaceuticals Ltd
  • Depression - Pipeline by Intra-Cellular Therapies Inc
  • Depression - Pipeline by INVENT Pharmaceuticals Inc
  • Depression - Pipeline by Johnson & Johnson
  • Depression - Pipeline by KemPharm Inc
  • Depression - Pipeline by Lead Discovery Center GmbH
  • Depression - Pipeline by Les Laboratoires Servier SAS
  • Depression - Pipeline by Lixte Biotechnology Holdings Inc
  • Depression - Pipeline by Luye Pharma Group Ltd
  • Depression - Pipeline by Mapi Pharma Ltd
  • Depression - Pipeline by Mapreg SAS
  • Depression - Pipeline by Medlab Clinical Ltd
  • Depression - Pipeline by Meta-IQ ApS
  • Depression - Pipeline by Methylation Sciences Inc
  • Depression - Pipeline by miCure Therapeutics Ltd
  • Depression - Pipeline by Mitsubishi Tanabe Pharma Corp
  • Depression - Pipeline by Navya Biologicals Pvt Ltd
  • Depression - Pipeline by Neuralstem Inc
  • Depression - Pipeline by Neurocrine Biosciences Inc
  • Depression - Pipeline by NeuroNascent Inc
  • Depression - Pipeline by NeurOp Inc
  • Depression - Pipeline by Newron Pharmaceuticals SpA
  • Depression - Pipeline by Nippon Chemiphar Co Ltd
  • Depression - Pipeline by nLife Therapeutics SL
  • Depression - Pipeline by Omeros Corp
  • Depression - Pipeline by Orexigen Therapeutics Inc
  • Depression - Pipeline by Otsuka Holdings Co Ltd
  • Depression - Pipeline by Pfizer Inc
  • Depression - Pipeline by Pherin Pharmaceuticals Inc
  • Depression - Pipeline by Polleo Pharma Ltd
  • Depression - Pipeline by Protagenic Therapeutics Inc
  • Depression - Pipeline by Relmada Therapeutics Inc
  • Depression - Pipeline by Reviva Pharmaceuticals Inc
  • Depression - Pipeline by Richter Gedeon Nyrt
  • Depression - Pipeline by Sage Therapeutics Inc
  • Depression - Pipeline by Saniona AB
  • Depression - Pipeline by SK Biopharmaceuticals Co Ltd
  • Depression - Pipeline by Sound Pharmaceuticals Inc
  • Depression - Pipeline by Sumitomo Dainippon Pharma Co Ltd
  • Depression - Pipeline by Supernus Pharmaceuticals Inc
  • Depression - Pipeline by Suven Life Sciences Ltd
  • Depression - Pipeline by Taisho Pharmaceutical Holdings Co Ltd
  • Depression - Pipeline by Takeda Pharmaceutical Company Ltd
  • Depression - Pipeline by Tetra Discovery Partners LLC
  • Depression - Pipeline by Trevena Inc
  • Depression - Pipeline by TRImaran Pharma Inc
  • Depression - Pipeline by VistaGen Therapeutics Inc
  • Depression - Pipeline by Zhejiang Huahai Pharmaceutical Co Ltd
  • Depression - Pipeline by Zogenix Inc
  • Depression - Pipeline by Zysis Ltd
  • Schizophrenia - Pipeline by Acadia Pharmaceuticals Inc
  • Schizophrenia - Pipeline by Adamed Sp z oo
  • Schizophrenia - Pipeline by Aequus Pharmaceuticals Inc
  • Schizophrenia - Pipeline by AgeneBio Inc
  • Schizophrenia - Pipeline by Alkermes Plc
  • Schizophrenia - Pipeline by Angita BV
  • Schizophrenia - Pipeline by Astellas Pharma Inc
  • Schizophrenia - Pipeline by Athersys Inc
  • Schizophrenia - Pipeline by Avanir Pharmaceuticals Inc
  • Schizophrenia - Pipeline by Avineuro Pharmaceuticals Inc
  • Schizophrenia - Pipeline by BCWorld Pharm Co Ltd
  • Schizophrenia - Pipeline by BioCrea GmbH
  • Schizophrenia - Pipeline by BioHealthonomics Inc
  • Schizophrenia - Pipeline by Boehringer Ingelheim GmbH
  • Schizophrenia - Pipeline by Braeburn Pharmaceuticals Inc
  • Schizophrenia - Pipeline by Bristol-Myers Squibb Company
  • Schizophrenia - Pipeline by Critical Pharmaceuticals Ltd
  • Schizophrenia - Pipeline by Curemark LLC
  • Schizophrenia - Pipeline by Daewoong Pharmaceutical Co Ltd
  • Schizophrenia - Pipeline by Delpor Inc
  • Schizophrenia - Pipeline by Denovo Biopharma LLC
  • Schizophrenia - Pipeline by Evotec AG
  • Schizophrenia - Pipeline by F. Hoffmann-La Roche Ltd
  • Schizophrenia - Pipeline by Fabre-Kramer Pharmaceuticals Inc
  • Schizophrenia - Pipeline by Galenea Corp
  • Schizophrenia - Pipeline by GeNeuro SA
  • Schizophrenia - Pipeline by GlaxoSmithKline Plc
  • Schizophrenia - Pipeline by Glenmark Pharmaceuticals Ltd
  • Schizophrenia - Pipeline by GP Pharm SA
  • Schizophrenia - Pipeline by GW Pharmaceuticals Plc
  • Schizophrenia - Pipeline by H. Lundbeck A/S
  • Schizophrenia - Pipeline by Heptares Therapeutics Ltd
  • Schizophrenia - Pipeline by Hisamitsu Pharmaceutical Co Inc
  • Schizophrenia - Pipeline by Indivior Plc
  • Schizophrenia - Pipeline by Insys Therapeutics Inc
  • Schizophrenia - Pipeline by IntelGenx Corp
  • Schizophrenia - Pipeline by Intra-Cellular Therapies Inc
  • Schizophrenia - Pipeline by Johnson & Johnson
  • Schizophrenia - Pipeline by JT Pharmaceuticals Inc
  • Schizophrenia - Pipeline by Karuna Pharmaceuticals Inc
  • Schizophrenia - Pipeline by KemPharm Inc
  • Schizophrenia - Pipeline by Kowa Company Ltd
  • Schizophrenia - Pipeline by Laboratorios Farmaceuticos Rovi SA
  • Schizophrenia - Pipeline by Lead Discovery Center GmbH
  • Schizophrenia - Pipeline by Lohocla Research Corp
  • Schizophrenia - Pipeline by Luye Pharma Group Ltd
  • Schizophrenia - Pipeline by Mapi Pharma Ltd
  • Schizophrenia - Pipeline by Merck & Co Inc
  • Schizophrenia - Pipeline by Mitsubishi Tanabe Pharma Corp
  • Schizophrenia - Pipeline by Neurocrine Biosciences Inc
  • Schizophrenia - Pipeline by NeurOp Inc
  • Schizophrenia - Pipeline by Newron Pharmaceuticals SpA
  • Schizophrenia - Pipeline by Omeros Corp
  • Schizophrenia - Pipeline by Otsuka Holdings Co Ltd
  • Schizophrenia - Pipeline by Peptron Inc
  • Schizophrenia - Pipeline by Pfizer Inc
  • Schizophrenia - Pipeline by Promentis Pharmaceuticals Inc
  • Schizophrenia - Pipeline by Ra Pharmaceuticals Inc
  • Schizophrenia - Pipeline by Reviva Pharmaceuticals Inc
  • Schizophrenia - Pipeline by Richter Gedeon Nyrt
  • Schizophrenia - Pipeline by Sage Therapeutics Inc
  • Schizophrenia - Pipeline by SK Biopharmaceuticals Co Ltd
  • Schizophrenia - Pipeline by Sumitomo Dainippon Pharma Co Ltd
  • Schizophrenia - Pipeline by Sunovion Pharmaceuticals Inc
  • Schizophrenia - Pipeline by Suven Life Sciences Ltd
  • Schizophrenia - Pipeline by Taisho Pharmaceutical Holdings Co Ltd
  • Schizophrenia - Pipeline by Tetra Discovery Partners LLC
  • Schizophrenia - Pipeline by Teva Pharmaceutical Industries Ltd
  • Schizophrenia - Pipeline by Vanda Pharmaceuticals Inc
  • Schizophrenia - Pipeline by Vitality Biopharma Inc
  • Schizophrenia - Pipeline by VLP Therapeutics LLC
  • Schizophrenia - Pipeline by Zogenix Inc
  • Schizophrenia - Pipeline by Zysis Ltd
  • Tourette Syndrome - Pipeline by Abide Therapeutics Inc
  • Tourette Syndrome - Pipeline by Catalyst Pharmaceuticals Inc
  • Tourette Syndrome - Pipeline by Neurocrine Biosciences Inc
  • Tourette Syndrome - Pipeline by Psyadon Pharmaceuticals Inc
  • Tourette Syndrome - Pipeline by Reviva Pharmaceuticals Inc
  • Tourette Syndrome - Pipeline by Synchroneuron Inc
  • Tourette Syndrome - Pipeline by Teva Pharmaceutical Industries Ltd
  • Tourette Syndrome - Pipeline by Therapix Biosciences Ltd
  • Attention Deficit Hyperactivity Disorder (ADHD) - Dormant Projects
  • Depression - Dormant Projects
  • Schizophrenia - Dormant Projects
  • Tourette Syndrome - Dormant Projects
  • Attention Deficit Hyperactivity Disorder (ADHD) - Discontinued Products
  • Depression - Discontinued Products
  • Schizophrenia - Discontinued Products
  • Tourette Syndrome - Discontinued Products

List of Figures

  • Number of Products under Development for Attention Deficit Hyperactivity Disorder (ADHD)
  • Number of Products under Development by Companies, Attention Deficit Hyperactivity Disorder (ADHD)
  • Number of Products under Development by Universities/Institutes, Attention Deficit Hyperactivity Disorder (ADHD)
  • Number of Products under Development for Depression
  • Number of Products under Development by Companies, Depression
  • Number of Products under Development by Universities/Institutes, Depression
  • Number of Products under Development for Schizophrenia
  • Number of Products under Development by Companies, Schizophrenia
  • Number of Products under Development by Universities/Institutes, Schizophrenia
  • Number of Products under Development for Tourette Syndrome
  • Number of Products under Development by Companies, Tourette Syndrome
  • Number of Products by Top 10 Targets, Attention Deficit Hyperactivity Disorder (ADHD)
  • Number of Products by Stage and Top 10 Targets, Attention Deficit Hyperactivity Disorder (ADHD)
  • Number of Products by Top 10 Mechanism of Actions, Attention Deficit Hyperactivity Disorder (ADHD)
  • Number of Products by Stage and Top 10 Mechanism of Actions, Attention Deficit Hyperactivity Disorder (ADHD)
  • Number of Products by Routes of Administration, Attention Deficit Hyperactivity Disorder (ADHD)
  • Number of Products by Stage and Routes of Administration, Attention Deficit Hyperactivity Disorder (ADHD)
  • Number of Products by Molecule Types, Attention Deficit Hyperactivity Disorder (ADHD)
  • Number of Products by Stage and Molecule Types, Attention Deficit Hyperactivity Disorder (ADHD)
  • Number of Products by Top 10 Targets, Depression
  • Number of Products by Stage and Top 10 Targets, Depression
  • Number of Products by Top 10 Mechanism of Actions, Depression
  • Number of Products by Stage and Top 10 Mechanism of Actions, Depression
  • Number of Products by Top 10 Routes of Administration, Depression
  • Number of Products by Stage and Top 10 Routes of Administration, Depression
  • Number of Products by Molecule Types, Depression
  • Number of Products by Stage and Molecule Types, Depression
  • Number of Products by Top 10 Targets, Schizophrenia
  • Number of Products by Stage and Top 10 Targets, Schizophrenia
  • Number of Products by Top 10 Mechanism of Actions, Schizophrenia
  • Number of Products by Stage and Top 10 Mechanism of Actions, Schizophrenia
  • Number of Products by Routes of Administration, Schizophrenia
  • Number of Products by Stage and Routes of Administration, Schizophrenia
  • Number of Products by Molecule Types, Schizophrenia
  • Number of Products by Stage and Molecule Types, Schizophrenia
  • Number of Products by Top 10 Targets, Tourette Syndrome
  • Number of Products by Stage and Top 10 Targets, Tourette Syndrome
  • Number of Products by Top 10 Mechanism of Actions, Tourette Syndrome
  • Number of Products by Stage and Top 10 Mechanism of Actions, Tourette Syndrome
  • Number of Products by Top 10 Routes of Administration, Tourette Syndrome
  • Number of Products by Stage and Routes of Administration, Tourette Syndrome
  • Number of Products by Stage and Molecule Types, Tourette Syndrome
Back to Top